Pharmacogenomics in the treatment of acute lymphoblastic leukemia in children
Journal Title: Medicina Fluminensis - Year 2008, Vol 44, Issue 1
Abstract
Over the past decades, the treatment of acute lymphoblastic leukemia in children has made remarkable progress. Pharmacogenomics of acute leukemias elucidates mechanisms of genetic control of antileukemic effects of chemotherapy and development of drug resistance. The aim of pharmacogenomic studies, related to the treatment of pediatric acute lymphoblastic leukemias, is to identify genes responsible for drug efficacy and toxicity, matched with the genetic makeup of every individual child. Pharmacogenomics offers the reasonable promise of therapeutic optimization and individualization, and further improvement of treatment outcome in childhood lymphoblastic leukemia.
Authors and Affiliations
Jelena Roganović
Keywords
Related Articles
- EP ID EP82887
- DOI -
- Views 96
- Downloads 0
Adolescent in family
Bioethics and bioethical aspects of palliative medicine
Palliative medicine is a medical discipline which deals with all forms of medical care or treatment which reduces the severity of disease symptoms, relieves suffering and improves the quality of life. The term “palliativ...
Quality and safety assurance of bone grafts stored by deep freezing method
Bone bank is a complex system which unifies collection, storage and distribution of bone grafts. In order to adequately use bone graft in bone and joint surgery, it must be tested microbiologically monitored and marked...
The discoid meniscus
Pharmacogenomics in the treatment of acute lymphoblastic leukemia in children
Over the past decades, the treatment of acute lymphoblastic leukemia in children has made remarkable progress. Pharmacogenomics of acute leukemias elucidates mechanisms of genetic control of antileukemic effects of chemo...